Tenderwize
Zurück zur Suche

Open House Rebate Contracts for Aripiprazole Depot Injection Suspension

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 28, 2027 · 187 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Aripiprazol, als Depot-Injektionssuspension, ATC N05AX12

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

62 / 100

Komplexität

58 / 100

Risikofaktoren

The structured data gives a submission deadline of 2027-02-28, while the notice text also refers to an initial deadline...

Electronic submission is not allowed and the notice requires original submission, which can affect validity if not foll...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive open-house rebate contracts for pharmaceutical products containing Aripiprazole as depot injection suspension.
  • Supply of approved and marketable medicines in Germany under uniform contract terms.
Vollständige Zusammenfassung anzeigen

Open-house supply arrangement for non-exclusive pharmaceutical rebate contracts for Aripiprazole depot injection suspension (ATC N05AX12) in Germany. The contracting buyer is AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse. No contract value is stated. Participation is open to interested pharmaceutical companies on uniform terms, but only approved and marketable medicines in Germany are eligible; pediatric medicines on the BfArM list are excluded. Submission is by original documents, not electronic submission, and the notice states that procurement documents are available via the document URL but no procurement document text beyond the XML notice was provided.

Risiken

The structured data gives a submission deadline of 2027-02-28, while the notice text also refers to an initial deadline...

Electronic submission is not allowed and the notice requires original submission, which can affect validity if not foll...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Only approved and marketable medicines in Germany may be supplied.

Administrative

  • If the medicine is not listed in Lauer-Taxe at submission time, an AMIce public extract must be provided.
  • The AMIce extract must show medicine name, marketing authorisation holder or equivalent entitlement, dosage form, active substance, and marketability.

Auftraggeber

Lose (1)

LOT-0001

Open House Rebate Contracts for Aripiprazole Depot Injection Suspension

Open-house non-exclusive rebate contracts for medicines containing Aripiprazole as depot injection suspension (ATC N05AX12). The lot covers uniform accession terms for pharmaceutical companies; no individual negotiation. Contracts can start on the first day of each month within the 24-month period, with the earliest start on 2025-05-01 and automatic end no later than 24 months after that date. The notice says the arrangement may later be replaced by exclusive rebate contracts through separate EU tenders. Pediatric medicines on the BfArM list are excluded. Lot information comes from structured data and XML notice.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

Apr 2025 - Apr 2027

Kategorie

Pharmaceutical products

Frist

Deadline Feb 28, 2027

Vergabedetails

Veröffentlichungsdatum
12 Mar 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
164511-2025

Dokumente (1)

Ähnliche Ausschreibungen